Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Bellicum Pharmaceuticals (BLCM) Stock Price

Media coverage about Bellicum Pharmaceuticals (NASDAQ:BLCM) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.111570561197 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

A number of research analysts recently commented on the stock. ValuEngine raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, September 18th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. BidaskClub raised shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Raymond James Financial, Inc. set a $18.00 price objective on shares of Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Wells Fargo & Company reissued an “outperform” rating and set a $31.00 price objective on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $26.20.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter in the prior year, the business posted ($0.61) EPS.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Bellicum Pharmaceuticals (BLCM) Stock Price” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://sportsperspectives.com/2017/10/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-bellicum-pharmaceuticals-blcm-stock-price.html.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Insider Buying and Selling by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply